Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Authors Randi J Hagerman, Deborah A Hall, Sarah Coffey, Maureen Leehey, James Bourgeois, et al

Published 6 June 2008 Volume 2008:3(2) Pages 251—262

DOI http://dx.doi.org/10.2147/CIA.S1794

Randi J Hagerman1,2, Deborah A Hall3, Sarah Coffey1,2, Maureen Leehey3, James Bourgeois4, John Gould5, Lin Zhang6, Andreea Seritan4, Elizabeth Berry-Kravis7–9, John Olichney6, Joshua W Miller10, Amy L Fong11, Randall Carpenter12, Cathy Bodine13, Louise W Gane1,2, Edgar Rainin1, Hillary Hagerman1, Paul J Hagerman14

1M.I.N.D. Institute, 2Department of Pediatrics, 4Department of Psychiatry & Behavioral Sciences, 5Department of Urology, 6Department of Neurology, 10Department of Pathology and Laboratory Medicine, 14Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA; 3Department of Neurology, University of Colorado, Denver, CO, USA; 7Department of Pediatrics, Neurology, and Biochemistry, 8Department of Neurological Sciences, 9Department of Biochemistry, Rush University Medical Center, Chicago, IL, USA; 11Physical Edge, Inc., Davis, CA, USA; 12Seaside Therapeutics, Cambridge, MA, USA; 13Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center, Denver, CO, USA

Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.

Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Lozano R, Hare EB, Hagerman RJ

Neuropsychiatric Disease and Treatment 2014, 10:1769-1779

Published Date: 16 September 2014

Readers of this article also read:

Mental health status, aggression, and poor driving distinguish traffic offenders from non-offenders but health status predicts driving behavior in both groups

Abdoli N, Farnia V, Delavar A, Esmaeili A, Dortaj F, Farrokhi N, Karami M, Shakeri J, Holsboer-Trachsler E, Brand S

Neuropsychiatric Disease and Treatment 2015, 11:2063-2070

Published Date: 10 August 2015

Sleep quality changes in insomniacs and non-insomniacs after acute altitude exposure and its relationship with acute mountain sickness

Tang XG, Zhang JH, Gao XB, Li QN, Li JB, Yu J, Qin J, Huang L

Neuropsychiatric Disease and Treatment 2014, 10:1423-1432

Published Date: 31 July 2014

Epidemiology of nonfatal stroke and transient ischemic attack in Al-Kharga District, New Valley, Egypt

Farghaly WM, El-Tallawy HN, Shehata GA, Rageh TA, Abdel-Hakeem NM, Elhamed MA, Al-Fawal BM, Badry R

Neuropsychiatric Disease and Treatment 2013, 9:1785-1790

Published Date: 18 November 2013

Preparation for high-acuity clinical placement: confidence levels of final-year nursing students

Porter J, Morphet J, Missen K, Raymond A

Advances in Medical Education and Practice 2013, 4:83-89

Published Date: 30 April 2013

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:73-81

Published Date: 13 January 2011

Diabetes, glycemic control and risk of medical glaucoma treatment: A population-based case-control study

Lotte G Welinder, Anders H Riis, Lars L Knudsen, et al

Clinical Epidemiology 2009, 1:125-131

Published Date: 21 October 2009

Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents

Roberto Canitano, Valeria Scandurra

Neuropsychiatric Disease and Treatment 2008, 4:723-730

Published Date: 8 August 2008

Functional MRI evidence for language plasticity in adult epileptic patients: Preliminary results

Emilie Cousin, Monica Baciu, Cédric Pichat1, Philippe Kahane, Jean-François Le Bas

Neuropsychiatric Disease and Treatment 2008, 4:235-246

Published Date: 8 February 2008